Analysis led by faculty from the Harvard T.H. Chan School of Public Health describes and analyzes how the deployment of substantial financial and human resources, expanded and novel forms of cooperation, and a range of innovations have contributed to the development of COVID-19 vaccines in record time.
Coronavirus disease 2019 (COVID-19) vaccine development and manufacturing have proceeded at a historically unprecedented pace. This speed may be accounted for by the unprecedented scale of resources being devoted to addressing COVID-19; an unusual intensity of cooperation, encompassing the public and private sectors and occurring both within and across national borders; and innovation with respect to both technologies (e.g., new vaccine platforms) and processes (e.g., vaccine clinical trials). In this article, we describe and analyze how resources, cooperation, and innovation have contributed to the accelerated development of COVID-19 vaccines. Similar levels and types of public investment, models of cooperation, and harnessing of innovative processes and technologies could be applied to future epidemics and other global health challenges.
View the document here.